Median PFS reached 15.5 months in the 120 mg palazestrant cohort across all comers, with 12.2 months among patients previously treated with a CDK4/6 inhibitor. Within that pretreated subgroup, median PFS was 13.8 months for ESR1-mutant tumors and 9.2 months for ESR1 wild-type tumors. In the 90 mg cohort, median PFS was not reached at 10.8 months of follow-up. Safety remained consistent with known profiles of the components, with most adverse events grade 1–2 and no observed drug–drug interactions with ribociclib.
Olema reported updated Phase 1b/2 data at ESMO 2025 for palazestrant (a CERAN/SERD) combined with ribociclib in ER+/HER2- advanced or metastatic breast cancer. The study enrolled 72 patients across 90 mg and 120 mg palazestrant dose levels, all with ribociclib at the approved metastatic dose. Sixty-three percent had prior CDK4/6 exposure in the advanced setting, and roughly a third of those carried ESR1 mutations at baseline. The company positions the dataset as supportive of its ongoing Phase 3 OPERA-02 trial testing palazestrant plus ribociclib as a first-line regimen.
Strategically, the move pushes palazestrant from a post-CDK4/6 salvage narrative into a backbone play aimed at displacing aromatase inhibitor plus CDK4/6 combinations in the front line. The signal across both ESR1-mutant and wild-type tumors attempts to sidestep the segmentation that confines elacestrant to ESR1-mutant disease and challenges the assumption that next-gen ER modulators must be biomarker-gated to deliver value. The tolerability profile and lack of observed pharmacokinetic interaction with ribociclib are operationally important if the goal is to scale a chronic, combination endocrine regimen without the dose attenuation and monitoring complexity that can erode adherence and site throughput.
For sites, an ESR1-agnostic efficacy signal, if sustained, would reduce preselection friction and reliance on rapid-turnaround ctDNA for trial entry, while still necessitating stratified analyses. Management would mirror standard ribociclib monitoring practices, which eases onboarding relative to unproven double-novel combinations. For sponsors and CROs, Olema’s design choice raises the bar on first-line trials: to change practice, randomized data must beat or at least match the durability seen with AI plus CDK4/6 in a cleaner population, not a mixed-line Phase 1b/2 cohort. Regulators will focus on subgroup consistency, prior CDK4/6 exposure, and durability beyond 12 months, alongside safety liabilities typical of CDK4/6 regimens. Vendors should expect continued demand for ESR1 testing to support stratification and exploratory endpoints, even if selection is not mandatory.
The central tension is comparability. A single-arm, heterogeneous study yielding a 15.5-month median PFS cannot be read against first-line benchmarks, where AI plus ribociclib historically delivers substantially longer PFS. The value in these data is directional: activity in post-CDK4/6 patients, a favorable safety read, and no apparent PK conflicts. To credibly reposition the first-line backbone, OPERA-02 must show superiority or at least a compelling risk–benefit advantage versus standard-of-care endocrine partner plus ribociclib, and it must do so across ESR1 strata and key clinical covariates.
Near term, watch for OPERA-02 design specifics and enrollment tempo, including control selection, ESR1 stratification, and interim analyses. Readouts from OPERA-01 (single-agent palazestrant post-CDK4/6) will also shape confidence in the drug’s intrinsic contribution outside the CDK4/6 umbrella. Competitive pressure is mounting from other next-gen ER antagonists moving into first-line combinations; any safety drift or efficacy dilution will be unforgiving in this head-to-head environment. The execution risk is clear: translating a mixed-line signal into a front-line practice change requires clean, randomized evidence and operational discipline across global sites that are already saturated with CDK4/6-based trials.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
